(Total Views: 531)
Posted On: 08/15/2022 11:10:16 PM
Post# of 148887
lastly according to the dr [you know who] m.d. anderson cancer ctr did a study with leronlimab and dostarlimab .this post below made in july 2022.would love to know more?
$CYDY conversation
@Jing
I can’t wait to read the MDA paper on checkpoint inhibitors ( dostarlimab) and Leronlimab synergy . This will be breakthrough designation . So it is possible that a BTD will be submitted using the combination of both these molecules after trials
$CYDY conversation
@Jing
I can’t wait to read the MDA paper on checkpoint inhibitors ( dostarlimab) and Leronlimab synergy . This will be breakthrough designation . So it is possible that a BTD will be submitted using the combination of both these molecules after trials
(1)
(0)Scroll down for more posts ▼
